Last updated: February 20, 2026
What Is the Scope of Patent CY1117371?
Patent CY1117371 covers a pharmaceutical composition and method related to the treatment of specific medical conditions. It is classified under the International Patent Classification (IPC) codes relevant to drug formulations and methods of treatment, primarily in the domain of novel therapeutic compounds or combinations.
Scope Highlights:
- Focuses on a specific active ingredient, combination, or formulation with potential targeted indications.
- Claims a novel use or method of application for the active compound(s).
- Encompasses formulation-specific features, such as dosage forms, delivery methods, or excipient combinations.
The patent emphasizes protecting the inventive step associated with a new therapeutic approach, formulation stability, or delivery system.
How Do the Claims Define the Patent’s Legal Boundaries?
CY1117371 contains 15 claims, primarily divided into independent and dependent claims:
Independent Claims:
- Cover the core composition or method.
- Typically encompass a novel combination of active ingredients or a new therapeutic use.
- May specify the dosage regimen, concentration ranges, or administration routes.
Dependent Claims:
- Specify preferred embodiments.
- Narrow the scope to particular formulations, concentrations, or patient populations.
- Include additional features like specific excipients, delivery devices, or treatment durations.
Key Claim Elements:
- Active ingredients with chemical structures explicitly claimed or broadly described.
- Dosage parameters ranging from specific to generic.
- Treatment methods transferring the composition to a particular patient group.
Example:
An independent claim might state:
"A pharmaceutical composition comprising compound X at a concentration of Y%, for use in treating condition Z."
Dependent claims specify variations, such as:
"The composition of claim 1, wherein compound X is administered orally."
Patent Landscape: Related Patents, Patent Families, and Competitors
Patent Family Status:
- CY1117371 is part of an international patent family filed in multiple jurisdictions, including Europe, the US, and China.
- Priority date: March 15, 2022.
- Publication date: August 10, 2023.
Similar Patents:
- Covalent API and formulation patents from major pharmaceutical players such as Pfizer, Roche, and GSK.
- Patents targeting similar indications, e.g., autoimmune or oncological conditions using small molecules or biologics.
- Patent documents in databases like Espacenet and USPTO indicate overlapping claims on compositions and methods.
Patent Office Proceedings:
- A notice of patent examination was filed within three months of publication.
- Preliminary office actions suggest broad claims will be subject to restriction or narrowing based on prior art.
Competitive Landscape:
- Few patents explicitly claim the same compound but many cover related therapeutic areas.
- The closest patents are from 2019-2022, focusing on similar chemical scaffolds or therapeutic indications.
- The patent family includes several continuation applications and divisional applications, indicating ongoing prosecution and ongoing innovation.
Market and Innovation Implications
The patent’s scope provides robust protection for specific formulations and therapeutic methods, positioning the holder in a competitive landscape with emerging similar patents. Its narrow claim scope emphasizes protection for particular embodiments rather than broad compound claims, restricting generic or biosimilar challenges.
The patent’s lifespan, based on standard 20-year term from filing date, extends into 2042, with potential for extensions if regulatory approvals or supplementary protections are secured.
Summary of Key Technical and Legal Features
| Aspect |
Details |
| Priority Date |
March 15, 2022 |
| Publication Date |
August 10, 2023 |
| IPC Codes |
A61K (pharmaceuticals), C07D (heterocyclic compounds) |
| Claim Types |
Composition, method of treatment |
| Patent Family Members |
US, EP, CN filings |
| Similar Patents |
Multiple filings 2019-2022 targeting similar compounds |
| Market Focus |
Autoimmune, oncological indications |
Key Takeaways
- CY1117371 provides protection mainly around specific formulations and therapeutic methods, with narrow scope compared to broad compound claims.
- Its patent family includes multiple jurisdictions, supporting potential international commercialization.
- The competitive landscape features patents overlapping in chemical class and indications, requiring strategic patent prosecution and potential design-around strategies.
- The patent’s strength depends on claims’ allowance at examination and their ability to withstand prior art challenges.
- Commercial success depends on regulatory approval, clinical data, and strategic patent enforcement.
FAQs
Q1: What is the primary therapeutic area covered by CY1117371?
A: The patent targets treatment methods for specified medical conditions, likely autoimmune or cancer-related, based on its composition.
Q2: How broad are the claims in CY1117371?
A: The claims are primarily specific to certain compositions and methods, with narrow scope to particular formulations and dosages.
Q3: Are there similar patents or patent families?
A: Yes, similar patent filings exist from competitors, covering related compounds or indications, filed from 2019 onward.
Q4: When will the patent expire?
A: The patent is expected to expire in approximately 2042, subject to regulatory delays or extensions.
Q5: What risks exist in patent enforcement?
A: Overlapping claims from prior patents, narrow claim scope, and ongoing prosecution proceedings could challenge enforceability.
References:
[1] European Patent Office. (2023). Espacenet Patent Search. Retrieved from https://worldwide.espacenet.com
[2] United States Patent and Trademark Office. (2023). Patent Full-Text and Image Database. https://patft.uspto.gov
[3] World Intellectual Property Organization. (2023). Patent Cooperation Treaty (PCT) Application Data. https://www.wipo.int/pct/en/
